[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:autoimmune-encephalitis":3},{"name":4,"total":5,"trials":6,"biomarkers":21,"states":22},"Autoimmune Encephalitis",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07220915","Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections",[11],"Phase 3","RECRUITING","2026-08-03T01:00:49.181319Z","2026-07-24T01:27:14.901588Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT05503264","A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis",[11],"2026-08-03T00:55:16.710581Z","2026-07-05T05:32:16.807804Z",[],[]]